Midatech Pharma plc

Symbol: MTP




Market price today

  • 0.0000

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 1.98M

    MRK Cap

  • 0.00%

    DIV Yield

Midatech Pharma plc (MTP) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Stephen A. Stamp
Full-time employees:20
Address:1 Caspian Point

Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

General Outlook

In simple terms, Midatech Pharma plc has 6.934 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep -6.312% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -12.778%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -10.953%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -1.386% return, is a testament to Midatech Pharma plc's adeptness in optimizing resource deployment. Midatech Pharma plc's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -1.125%. Furthermore, the proficiency of Midatech Pharma plc in capital utilization is underscored by a remarkable -2.464% return on capital employed.

Stock Prices

Midatech Pharma plc's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.24, while its low point bottomed out at $0.2. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Midatech Pharma plc's stock market.

Liquidity Ratios

Analyzing MTP liquidity ratios reveals its financial health of the firm. The current ratio of 246.74% gauges short-term asset coverage for liabilities. The quick ratio (149.26%) assesses immediate liquidity, while the cash ratio (149.26%) indicates cash reserves.

Current Ratio246.74%
Quick Ratio149.26%
Cash Ratio149.26%

Profitability Ratios

MTP profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -1214.31% underscores its earnings before tax deductions. The effective tax rate stands at 9.80%, revealing its tax efficiency. The net income per EBT, 90.20%, and the EBT per EBIT, 95.03%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -1277.83%, we grasp its operational profitability.

Pretax Profit Margin-1214.31%
Effective Tax Rate9.80%
Net Income per EBT90.20%
EBT per EBIT95.03%
EBIT per Revenue-1277.83%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 2.47, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

Days of Sales Outstanding149
Days of Payables Outstanding103
Cash Conversion Cycle-103
Payables Turnover3.53
Fixed Asset Turnover0.84
Asset Turnover0.13

Cash Flow Ratios

Lastly, the operating cash flow sales ratio, -10.08, offers insight into cash flow relative to sales.

Operating Cash Flow Sales Ratio-10.08
Free Cash Flow to Operating Cash Flow Ratio1.01
Cash Flow Coverage Ratio-11.29
Short Term Coverage Ratio-43.78
Capital Expenditure Coverage Ratio-113.68
Dividend Paid and Capex Coverage Ratio-113.68

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 11.29%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.20, we discern the balance between debt and equity financing. The long-term debt to capitalization, 12.77%, and total debt to capitalization, 16.48%, ratios shed light on its capital structure. An interest coverage of -168.53 indicates its ability to manage interest expenses.

Debt Ratio11.29%
Debt Equity Ratio0.20
Long Term Debt to Capitalization12.77%
Total Debt to Capitalization16.48%
Interest Coverage-168.53
Cash Flow to Debt Ratio-11.29
Company Equity Multiplier1.75

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, -2,212,000, captures the company's total value, considering both debt and equity. Income quality, 0.92, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 6.50, gauges operational efficiency, while the research and development to revenue, 731.19%, highlights investment in innovation. The ratio of intangibles to total assets, 0.11%, indicates the value of non-physical assets, and capex to operating cash flow, 0.88%, measures reinvestment capability.

Enterprise Value-2,212,000
Income Quality0.92
Sales General and Administrative to Revenue6.50
Research and Development to Revenue731.19%
Intangibles to Total Assets0.11%
Capex to Operating Cash Flow0.88%
Capex to Revenue-8.87%
Capex to Depreciation-18.08%
Stock-Based Compensation to Revenue17.60%
Return on Tangible Assets-138.72%
Working Capital2,788,000
Tangible Asset Value3,156,000
Net Current Asset Value2,325,000
Average Payables1,269,500
Days Payables Outstanding103

Valuation Ratios

The price to sales ratio, 2.83, provides a perspective on valuation in relation to sales.

Price to Sales Ratio2.83
Enterprise Value Multiple-0.49
Price to Free Cash Flows Ratio-0.28
Enterprise Value to Sales-3.16
Enterprise Value Over EBITDA0.26
EV to Operating Cash Flow0.31
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Midatech Pharma plc (MTP) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 0.000 in 2024.

What is the ticker symbol of Midatech Pharma plc stock?

The ticker symbol of Midatech Pharma plc stock is MTP.

What is company IPO date?

IPO date of Midatech Pharma plc is 2015-12-07.

What is company current share price?

Current share price is 0.285 USD.

What is stock market cap today?

The market cap of stock today is 1976846.000.

What is PEG ratio in 2024?

The current 0.000 is 0.000 in 2024.

What is the number of employees in 2024?

In 2024 the company has 20.